< Back to latest news & events

Articles

Protecting inventions in Europe and beyond

February 2025

A patent is  a form of registered intellectual property right granted for new, inventive and industrially applicable inventions. Patents are monopoly rights that  allow their owners (or licensees) the right to work an invention while the patent is in force. Securing patent protection for an invention has many advantages for businesses, for example, assisting in obtaining  investment, establishing or maintaining a leading position in the market or providing a source of revenue from licensing royalties.

Patents are jurisdictional. As such, patent protection has to be obtained in each country of interest and this can incur significant costs. One commonly used patent filing strategy to spread out and defer such costs is shown below, and this makes use of the Patent Co-operation Treaty (PCT) application process.

In this example, the applicant files their initial patent application – the priority application. For most UK based companies, it makes sense to file this application at the UK Intellectual Property Office (UKIPO) because of the relatively inexpensive official fees. It is also possible to obtain a quality search from the UK within about 6 months from the initial filing date. The search report can provide information about the state of the art and allow an informed decision on the future investment in the patent application.

Within twelve months from the filing date of the priority application – the priority year – the applicant can file subsequent patent applications directed to the same invention as that disclosed in the priority application and “claim priority” .This means that the novelty and inventiveness of the subsequent applications are examined against any known disclosure (prior art) before the priority date.

Applicants tend to seek patent protection in countries where they manufacture, sell, import or have potential licensees.  If the applicant were to file patent applications in each of these countries at the 12 month stage, this could require significant expenditure. Therefore, instead the applicant can chose to file what is known as an international application (PCT). This essentially creates a pending patent application which has the potential to be taken further forward in 158 countries. The applicant then has a further 18 months from the filing date of the PCT application to determine which countries of interest they wish to pursue obtaining patent protection. During this time, a further search report will be issued and the application will be published. Publication of the PCT application occurs at around 18 months from the priority date and in some instances can establish provisional patent protection.

In the example, at 30/31 months from the priority date, the applicant has chosen to pursue patent protection in the US, Japan and Europe. By entering the PCT application into the European patent office, the applicant now has a pending European application which can cover 39 countries. If the European patent application is granted, the applicant can choose which of these countries they wish to have a granted patent in by validating the patent in those countries. The option now also exists to obtain an Unitary Patent that covers 18 countries in the EU via a single patent. In the example above, the applicant would validate as a Unitary Patent and in the UK, or alternatively in the UK, France and Germany. The applicant also has a pending US and a pending Japanese patent application. Each of these applications will subsequently be examined by the patent office in these jurisdictions and could go on to form granted US and JP patents.


This article was written by Patent Director Clara Orofino

Latest updates

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 7th January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article